Characterization of a new membrane from concentrated growth factors associated with denaturized Albumin (Alb-CGF) for clinical applications: A preliminary study

Mourão, Carlos Fernando de Almeida Barros; Gheno, Ezio; Lourenço, Emanuelle Stellet; Barbosa, Renata de Lima; Kurtzman, Gregori M; Javid, Kayvon; Mavropoulos, Elena; Benedicenti, Stefano; Calasans-Maia, Mônica Diuana; Mello-Machado, Rafael Coutinho; Alves, Gutemberg Gomes

doi:10.4103/gfsc.gfsc_21_18

Cited by 37 publications

(32 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…An article evaluated the performance of APC associated with albumin [ 32 ] which could represent a possible improvement in its framework, modulating the fibrin network ultrastructure and permeability. Also, the material produced in this study showed to have higher biocompatibility, and possibly more durable with a greater thickness and resistance [ 32 , 33 ]. However, the levels of released cytokines and growth factors were similar to those found for PRF; also, its degradation period is compatible with PRF extending to almost 10 days [ 1 , 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Controversially, although other techniques [ 28 , 32 ] exist, the simplest way is to follow the protocols strictly using the correct centrifugation settings to obtain the correct membrane. Thus, the results obtained for L-PRF in this study (average of 0.02260 MPa) is in perfect agreement with the resistance of L-PRF published by Khorshidi et al [ 22 ] (0.20 ± 0.06 MPa), but strangely, Ravi and Santhanakrishnan (2020) [ 26 ] found an extremely higher value for L-PRF (290.076 ± 5.68 MPa).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

et al. 2021

View full text Add to dashboard Cite

Background Since the leucocyte-platelet rich fibrin (L-PRF) was published in 2001, many studies have been developed, analyzing its properties, and also verifying new possibilities to improve it. Thereby, it emerges the advanced-platelet rich fibrin (A-PRF) with a protocol that optimizes the properties obtained by the L-PRF. Nonetheless, there is a gap in the literature to landmark the evolutive process concerning the mechanical properties in specific the resistance to tensile strength which consequently may influence the time for membrane degradation. Thus, this study had the goal to compare the resistance to the traction of membranes produced with the original L-PRF and A-PRF protocols, being the first to this direct comparison. Findings The harvest of blood from a healthy single person, with no history of anticoagulant usage. We performed the protocols described in the literature, within a total of 13 membranes produced for each protocol (n = 26). Afterward, the membranes were prepared and submitted to a traction test assessing the maximal and the average traction achieved for each membrane. The data were analyzed statistically using the unpaired t test. Regarding average traction, A-PRF obtained a value of 0.0288 N mm−2 and L-PRF 0.0192 N mm−2 (p < 0.05 using unpaired t test). For maximal traction, A-PRF obtained 0.0752 N mm−2 and L-PRF 0.0425 N mm−2 (p < 0.05 using unpaired t test). Conclusion With this study, it was possible to conclude that indeed A-PRF has a significative higher maximal traction score and higher average traction compared to L-PRF, indicating that it had a higher resistance when two opposing forces are applied.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…They found that the heating could modify the native PRF membrane to be used as a barrier for guided bone regeneration procedures. Similar to this concept, Mourão et al [86] conducted an in vitro study, in which they heated the blood serum and a portion of plasma low in platelets, subsequently incorporating PRP or liquid PRF for the inclusion of cells; consequently, the possibility of releasing growth factors and other cytokines. At the time, the product was called Alb-CGF, corresponding to the albumin produced by the heating process, with the incorporation of the concentrate of growth factors [86,87].…”

Section: Controlled Release Of Growth Factors Retained In Prf Matricesmentioning

confidence: 99%

“…Similar to this concept, Mourão et al [86] conducted an in vitro study, in which they heated the blood serum and a portion of plasma low in platelets, subsequently incorporating PRP or liquid PRF for the inclusion of cells; consequently, the possibility of releasing growth factors and other cytokines. At the time, the product was called Alb-CGF, corresponding to the albumin produced by the heating process, with the incorporation of the concentrate of growth factors [86,87]. Recently, the same group carried out new studies in vitro in order to assess the biocompatibility of this method [88].…”

Section: Controlled Release Of Growth Factors Retained In Prf Matricesmentioning

confidence: 99%

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

2020

View full text Add to dashboard Cite

The ultimate goal of research on platelet concentrates (PCs) is to develop a more predictable PC therapy. Because platelet-rich plasma (PRP), a representative PC, was identified as a possible therapeutic agent for bone augmentation in the field of oral surgery, PRP and its derivative, platelet-rich fibrin (PRF), have been increasingly applied in a regenerative medicine. However, a rise in the rate of recurrence (e.g., in tendon and ligament injuries) and adverse (or nonsignificant) clinical outcomes associated with PC therapy have raised fundamental questions regarding the validity of the therapy. Thus, rigorous evidence obtained from large, high-quality randomized controlled trials must be presented to the concerned regulatory authorities of individual countries or regions. For the approval of the regulatory authorities, clinicians and research investigators should understand the real nature of PCs and PC therapy (i.e., adjuvant therapy), standardize protocols of preparation (e.g., choice of centrifuges and tubes) and clinical application (e.g., evaluation of recipient conditions), design bias-minimized randomized clinical trials, and recognize superfluous brand competitions that delay sound progress. In this review, we retrospect the recent past of PC research, reconfirm our ultimate goals, and discuss what will need to be done in future.

show abstract

Autologous blood products: Usage and preparation protocols

Palaiologou

Keeling

2022

Clin Adv Periodontics

View full text Add to dashboard Cite

Focused clinical question What are the appropriate preparation protocols for autologous blood products to support their clinical utilization? Summary Autologous blood products provide a unique clinical benefit. Their popularity among the professions is growing. However, as this is a rapidly evolving field, multiple modalities are presented within the literature. Frequently there is no demonstrated superiority to previous iterations. This brief review attempts to offer a concise chronology on their evolution, preparation, and where possible, evidence to support their clinical utilization. Conclusions The field of autologous blood products is expanding rapidly. These products appear to yield variable clinical benefits in specific indications. However, evidence supporting their universal application is scant, and the superiority of one formulation versus another is yet to be demonstrated.

show abstract

Characterization of a new membrane from concentrated growth factors associated with denaturized Albumin (Alb-CGF) for clinical applications: A preliminary study

Cited by 37 publications

References 3 publications

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

Tensile strength assay comparing the resistance between two different autologous platelet concentrates (leucocyte-platelet rich fibrin versus advanced-platelet rich fibrin): a pilot study

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

Autologous blood products: Usage and preparation protocols

Contact Info

Product

Resources

About